Treprostinil for pulmonary hypertension

References

• BadeschDBAbmanSHSimonneauGMedical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelinesChest200713119172817565025
   PubMed Web of Science ®Google Scholar
• BadeschDBTapsonVFMcGoonMDContinuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trialAnn Intern Medi200013242534
   PubMed Web of Science ®Google Scholar
• BarstRJGalieNNaeijeRLong-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinilEur Respir J200628119520316899485
   PubMed Web of Science ®Google Scholar
• BarstRJRubinLJLongWAA comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertensionN Engl J Med19963342963018532025
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension, seven sites, United StatesMorb Mortal Wkly Rep2007561702
   PubMedGoogle Scholar
• ChannickRNOlschewskiHSeegerWSafety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertensionJ Am Coll Cardiol2006481433717010807
   PubMed Web of Science ®Google Scholar
• FarberHWLoscalzoJPulmonary arterial hypertensionN Engl J Med200435116556515483284
   PubMed Web of Science ®Google Scholar
• GalieNTorbickiABarstRTask ForceGuidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of CardiologyEur Heart J20042522437815589643
   PubMed Web of Science ®Google Scholar
• Gomberg-MaitlandMTapsonVFBenzaRLTransition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertensionAm J Respir Crit Care Med20051721586916151039
   PubMed Web of Science ®Google Scholar
• HigenbottamTWSpiegelhalterDScottJPProstacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertensionBr Heart J199370366708217447
   PubMedGoogle Scholar
• HoeperMMMayerESimonneauGChronic thromboembolic pulmonary hypertensionCirculation200611320112016636189
   PubMed Web of Science ®Google Scholar
• HumbertMSitbonOSimonneauGTreatment of pulmonary arterial hypertensionN Engl J Med200435114253615459304
   PubMed Web of Science ®Google Scholar
• HumbertMSitbonOChaouatAPulmonary arterial hypertension in France: results from a national registryAm J Respir Crit Care Med200617310233016456139
   PubMed Web of Science ®Google Scholar
• KuoPCPlotkinJSHowellCDContinuous infusion of epoprostenol for the treatment of portopulmonary hypertensionTransplantation19976360469047158
   PubMed Web of Science ®Google Scholar
• LaliberteKArnesonCJeffsRPharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteersJ Cardiovasc Pharmacol2004442091415243302
   PubMed Web of Science ®Google Scholar
• LangIGomez-SanchezMKneusslMEfficacy of long-terms subcutaneous treprostinil sodium therapy in pulmonary hypertensionChest200612916364316778286
   PubMed Web of Science ®Google Scholar
• McLaughlinVPresbergKWDoyleRLPrognosis of pulmonary arterial hypertension* ACCP evidence-based clinical practice guidelinesChest200412678S92S15249497
   PubMed Web of Science ®Google Scholar
• McLaughlinVVShillingtonARichSSurvival in primary pulmonary hypertension: the impact of epoprostenol therapyCirculation200210614778212234951
   PubMed Web of Science ®Google Scholar
• McSwainCSBenzaRShapiroSDose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusionsJ Clin Pharmacol200848192518094217
   PubMed Web of Science ®Google Scholar
• NaeijeRVachieryJLMedical therapy of pulmonary hypertension: conventional therapiesClin Chest Med2001225172811590845
   PubMed Web of Science ®Google Scholar
• NagayaNSasakiNAndoMProstacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertensionChest20031233384312576349
   PubMed Web of Science ®Google Scholar
• NunesHHumbertMSitbonOPrognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertensionAm J Respir Crit Care Med20031671433912615632
   PubMed Web of Science ®Google Scholar
• PeacockAJMurphyNFMcMurrayJJVAn epidemiological study of pulmonary arterial hypertensionEur Respir J200730104917360728
   PubMed Web of Science ®Google Scholar
• PharesKRWeiserWEMillerSPStability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluentsAm J Health Syst Pharm2003609162212756943
   PubMed Web of Science ®Google Scholar
• ProvencherSSitbonOHumbertMLong-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertensionEur Heart J20062758959516431875
   PubMed Web of Science ®Google Scholar
• RobbinsIMChristmanBWNewmanJHA survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertensionChest19981141269759824000
   PubMed Web of Science ®Google Scholar
• RosenzweigEBKersteinDBarstRJLong-term prostacyclin for pulmonary hypertension with associated congenital heart defectsCirculation19999918586510199883
   PubMed Web of Science ®Google Scholar
• RubenfireMMcLaughlinVVAllenRPTransition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trialChest20071327576317400684
   PubMed Web of Science ®Google Scholar
• SimonneauGBarstRJGaliéNContinuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertensionAm J Respir Crit Care Med2002162800411897647
   PubMedGoogle Scholar
• SimonneauGGalieNRubinLJClinical classification of pulmonary hypertensionJ Am Coll Cardiol20044312 Suppl S5S12S15194173
   PubMed Web of Science ®Google Scholar
• SitbonOHumbertMNunesHLong-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survivalJ Am Coll Cardiol200240780812204511
   PubMed Web of Science ®Google Scholar
• SitbonOManesAJaisXRapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertensionJ Cardiovasc Pharmacol2007491517261956
   PubMed Web of Science ®Google Scholar
• Skoro-SajerNBondermanDWiesbauerFTreprostinil for severe inoperable chronic thromboembolic pulmonary hypertensionJ Thomb Haemost200754839
   PubMed Web of Science ®Google Scholar
• TapsonVFGomberg-MaitlandMMcLaughlinVVSafety and efficacy of iv treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trialChest2006129683816537868
   PubMed Web of Science ®Google Scholar
• VachieryJLHillNZwickeDTransitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertensionChest20021211561512006444
   PubMed Web of Science ®Google Scholar
• VachieryJLNaeijeRTreprostinil for pulmonary hypertensionExpert Rev Cardiovasc Ther200421839115151467
   PubMedGoogle Scholar
• WadeMBakerFJRoscignoRAbsolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusionJ Clin Pharmacol20044483814681345
   PubMed Web of Science ®Google Scholar
• WadeMHuntTLLaiAAEffect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarinJ Cardiovasc Pharmacol2003419081512775969
   PubMed Web of Science ®Google Scholar